403 related articles for article (PubMed ID: 34638296)
1. Management of Resectable Stage III-N2 Non-Small-Cell Lung Cancer (NSCLC) in the Age of Immunotherapy.
Mielgo-Rubio X; Montemuiño S; Jiménez U; Luna J; Cardeña A; Mezquita L; Martín M; Couñago F
Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638296
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant therapy for resectable non-small cell lung cancer with mediastinal lymph node involvement.
Tieu BH; Sanborn RE; Thomas CR
Thorac Surg Clin; 2008 Nov; 18(4):403-15. PubMed ID: 19086609
[TBL] [Abstract][Full Text] [Related]
3. A review of perioperative treatment strategies with immunotherapy and tyrosine kinase inhibitors in resectable and stage IIIA-N2 non-small cell lung cancer.
Hopson MB; Rashdan S
Front Oncol; 2024; 14():1373388. PubMed ID: 38601764
[TBL] [Abstract][Full Text] [Related]
4. Current status and future perspectives on immunotherapy in neoadjuvant therapy of resectable non-small cell lung cancer.
Liu X; Xing H; Liu H; Chen J
Asia Pac J Clin Oncol; 2022 Aug; 18(4):335-343. PubMed ID: 34811893
[TBL] [Abstract][Full Text] [Related]
5. An Updated Review of Management of Resectable Stage III NSCLC in the Era of Neoadjuvant Immunotherapy.
Verma S; Breadner D; Mittal A; Palma DA; Nayak R; Raphael J; Vincent M
Cancers (Basel); 2024 Mar; 16(7):. PubMed ID: 38610980
[TBL] [Abstract][Full Text] [Related]
6. Pharmacodynamics of Pre-Operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multicentre, open-label, phase 1B/2, translational trial (POPCORN).
Ahern E; Cubitt A; Ballard E; Teng MWL; Dougall WC; Smyth MJ; Godbolt D; Naidoo R; Goldrick A; Hughes BGM
Trials; 2019 Dec; 20(1):753. PubMed ID: 31856909
[TBL] [Abstract][Full Text] [Related]
7. Induction treatment in patients with stage III non-small cell lung cancer.
Palmero R; Vilariño N; Navarro-Martín A; Nadal E
Transl Lung Cancer Res; 2021 Jan; 10(1):539-554. PubMed ID: 33569335
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy in Early-Stage Non-Small Cell Lung Cancer (NSCLC): Current Evidence and Perspectives.
Lazzari C; Spagnolo CC; Ciappina G; Di Pietro M; Squeri A; Passalacqua MI; Marchesi S; Gregorc V; Santarpia M
Curr Oncol; 2023 Mar; 30(4):3684-3696. PubMed ID: 37185393
[TBL] [Abstract][Full Text] [Related]
9. Is There a Survival Benefit in Patients With Stage IIIA (N2) Non-small Cell Lung Cancer Receiving Neoadjuvant Chemotherapy and/or Radiotherapy Prior to Surgical Resection: A Systematic Review and Meta-analysis.
Xu YP; Li B; Xu XL; Mao WM
Medicine (Baltimore); 2015 Jun; 94(23):e879. PubMed ID: 26061306
[TBL] [Abstract][Full Text] [Related]
10. Phase II Study of Neoadjuvant Concurrent Chemo-immuno-radiation Therapy Followed by Surgery and Adjuvant Immunotherapy for Resectable Stage IIIA-B (Discrete N2) Non-small-cell Lung Cancer: SQUAT trial (WJOG 12119L).
Hamada A; Soh J; Hata A; Nakamatsu K; Shimokawa M; Yatabe Y; Oizumi H; Tsuboi M; Horinouchi H; Yoshino I; Tanahashi M; Toyooka S; Okada M; Yokomise H; Yamashita M; Nishimura Y; Yamamoto N; Nakagawa K; Mitsudomi T
Clin Lung Cancer; 2021 Nov; 22(6):596-600. PubMed ID: 34034990
[TBL] [Abstract][Full Text] [Related]
11. Stage 3 N2 Lung Cancer: A Multidisciplinary Therapeutic Conundrum.
Carter L; Apte V; Shukla A; Ghose A; Mamidi R; Petohazi A; Makker S; Banerjee S; Boussios S; Banna GL
Curr Oncol Rep; 2024 Jan; 26(1):65-79. PubMed ID: 38180692
[TBL] [Abstract][Full Text] [Related]
12. Stage III Non-small Cell Lung Cancer: A UK National Survey of Practice.
Evison M; Edwards J; McDonald F; Popat S
Clin Oncol (R Coll Radiol); 2020 Aug; 32(8):527-536. PubMed ID: 32216979
[TBL] [Abstract][Full Text] [Related]
13. Stage III N2 non-small cell lung cancer treatment: decision-making among surgeons and radiation oncologists.
Glatzer M; Leskow P; Caparrotti F; Elicin O; Furrer M; Gambazzi F; Dutly A; Gelpke H; Guckenberger M; Heuberger J; Inderbitzi R; Cafarotti S; Karenovics W; Kestenholz P; Kocher GJ; Kraxner P; Krueger T; Martucci F; Oehler C; Ozsahin M; Papachristofilou A; Wagnetz D; Zaugg K; Zwahlen D; Opitz I; Putora PM
Transl Lung Cancer Res; 2021 Apr; 10(4):1960-1968. PubMed ID: 34012806
[TBL] [Abstract][Full Text] [Related]
14. Update on the Management of Stage III NSCLC: Navigating a Complex and Heterogeneous Stage of Disease.
Sathiyapalan A; Baloush Z; Ellis PM
Curr Oncol; 2023 Oct; 30(11):9514-9529. PubMed ID: 37999109
[TBL] [Abstract][Full Text] [Related]
15. [Review on Treatment Modalities for Resectable IIIa/N2 Non-small Cell Lung Cancer].
Xu Z; Xing P; Ma D; Zhu Y; Ying J; Li J
Zhongguo Fei Ai Za Zhi; 2019 Feb; 22(2):111-117. PubMed ID: 30827328
[TBL] [Abstract][Full Text] [Related]
16. Short-term outcome of neoadjuvant immunotherapy and chemotherapy in non-small cell lung cancer: A systematic review and meta-analysis.
Zhang C; Hong HZ; Wu YL; Zhong WZ
JTCVS Open; 2021 Dec; 8():588-607. PubMed ID: 36004199
[TBL] [Abstract][Full Text] [Related]
17. The new era of immune checkpoint inhibition and target therapy in early-stage non-small cell lung cancer. A review of the literature.
Catania C; Muthusamy B; Spitaleri G; Del Signore E; Pennell NA
Clin Lung Cancer; 2022 Mar; 23(2):108-115. PubMed ID: 34952792
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant and neo-adjuvant immunotherapy in resectable non-small cell lung cancer (NSCLC): Current status and perspectives.
Xu Z; Zou Z; Hao X; Xing P; Li J
Cancer Innov; 2023 Feb; 2(1):65-78. PubMed ID: 38090369
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant and adjuvant epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy for lung cancer.
Zhai H; Zhong W; Yang X; Wu YL
Transl Lung Cancer Res; 2015 Feb; 4(1):82-93. PubMed ID: 25806348
[TBL] [Abstract][Full Text] [Related]
20. Optimum treatment for mediastinal lymph node positive (N2) resectable non-small cell lung cancer: what is the role for surgery?
Awan M; Sharma N; Towe CW; Efird JT; Machtay M; Biswas T
Expert Rev Anticancer Ther; 2016 Nov; 16(11):1131-1144. PubMed ID: 27654059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
